Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Overcoming Why a New Treatment is Resisted by Lung Cancer

July 29, 2015 10:56 am | by University of Manchester | News | Comments

A promising agent for the treatment of cancer has so far had little effect on the most common lung tumours, but new research from The University of Manchester has suggested how this resistance might be overcome. Read more...


Sanofi Announces that First LixiLan Phase 3 Study Met Primary Endpoint

July 29, 2015 10:50 am | News | Comments

Sanofi announced yesterday that the LixiLan-O Phase 3 clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL. Read more...


Indivior: FDA Acceptance of Naloxone Nasal Spray NDA With Priority Review

July 29, 2015 10:39 am | News | Comments

Indivior PLC today announced that the New Drug Application (NDA) for naloxone nasal spray was accepted and received Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of opioid overdose.  Read more..


Apogenix to Collaborate with R-Biopharm to Develop Immuno-Oncology Diagnostic Tests

July 29, 2015 10:24 am | News | Comments

Apogenix, a next generation immuno-oncology company, announced today that it has entered into an agreement with R-Biopharm, a global provider of innovative clinical diagnostics, to develop companion diagnostic tests for Apogenix' lead drug candidate APG101. APG101 is a CD95 ligand inhibitor which restores the body's immune response against tumors and inhibits invasive tumor cell growth.  Read more...


Gene Therapy Makes Near-Blind Patients See by Strengthening Neural Connections

July 29, 2015 10:13 am | by Cynthia Fox, Science Editor | Articles | Comments

Gene therapy restored vision to blind patients by strengthening visual pathways from the retina, through the brain’s white matter, into the brain’s visual cortex, says a report in Science Translational Medicine. Read more...


Naturally Occurring Protein Fragment Found in Brain Inhibits Key Enzyme Implicated In Alzheimer's

July 29, 2015 10:04 am | by UCLA | News | Comments

For the first time, UCLA researchers have shown that a natural protein fragment produced in the brain can act as an inhibitor of a key enzyme implicated in the onset of Alzheimer's disease, a finding that could lead to the development of new drugs to treat the disease. Read more...


Closing the Gap on Developing a Vaccine for Middle Ear Infections

July 29, 2015 10:00 am | by Griffith University | News | Comments

Researchers from Griffith University's Institute for Glycomics, together with the Nationwide Children's Hospital in Ohio, have uncovered groundbreaking evidence to help vaccine developers prevent middle ear infections. Read more...


Boehringer Ingelheim to Collaborate with Hanmi Pharmaceutical to Develop Lung Cancer Therapy

July 29, 2015 9:51 am | News | Comments

Boehringer Ingelheim and Hanmi Pharmaceutical Co., Ltd. today announced an exclusive license and collaboration agreement for the development and global commercialization rights, except South Korea, China and Hong Kong, of HM61713, a novel 3rd generation EGFR targeted therapy for the treatment of a specific type of lung cancer. Read more...


Study Identifies 'Major Player' in Skin Cancer Genes

July 29, 2015 9:46 am | by Yale University | News | Comments

A multidisciplinary team at Yale, led by Yale Cancer Center members, has defined a subgroup of genetic mutations that are present in a significant number of melanoma skin cancer cases. Their findings shed light on an important mutation in this deadly disease, and may lead to more targeted anti-cancer therapies. Read more...


Four-Pronged Flu Prevention

July 29, 2015 9:39 am | by Lindsay Hock, Editor | Articles | Comments

Now, (July/August) is the time frame when flu vaccines start to be delivered to protect the public for next year. Yet, the road to an efficient vaccine is a difficult one. Just as with any virus, influenza mutates in its genetic material, potentially causing changes in the strains present each year. Read more...


Gilead Beats Street 2Q Forecasts on Surge in Sales, Profit

July 29, 2015 9:22 am | by Linda A. Johnson, AP Business Writer | News | Comments

Blockbuster hepatitis C medicine Harvoni propelled Gilead Sciences Inc.'s second-quarter profit up 23 percent as total revenue for the biotech drugmaker jumped 26 percent and it raised its 2015 sales forecast for the second time. Its shares jumped in after-hours trading. Read more...


Drugmaker GSK Sees Earnings Growth Returning in 2016

July 29, 2015 8:45 am | by The Associated Press | News | Comments

Synergy benefits are expected when the transaction begins to contribute more meaningfully. Read more...


Merck Tops Street 2Q Forecasts Despite Lower Sales, Profits

July 29, 2015 8:41 am | by Linda A. Johnson, AP Business Writer | News | Comments

The company noted experimental hepatitis C combination pill grazoprevir/elbasvir is now being reviewed by regulators in the U.S. and European Union. Read more...


Experimental MERS Vaccine Shows Promise in Animal Studies

July 29, 2015 8:40 am | by NIAID | News | Comments

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques. Read more...


Roche's Atezolizumab Could Spur Long-Awaited Bladder Cancer Treatment Innovation

July 29, 2015 8:40 am | by Cai Xuan, Ph.D., Oncology and Hematology, GlobalData | Articles | Comments

This observation opens up a market for companion biomarker tests that can be used to identify patients who would likely benefit from PD-1/PD-L1-targeted therapies. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.